New york: The U.S. Food and Drug Administration (FDA) has given the green light to 20 nicotine pouches, allowing them to be marketed as Modified Risk Tobacco Products (MRTPs) after a stringent review process. This decision comes as part of the FDA's efforts to provide adult tobacco users with products that present lower health risks compared to traditional smoking.
According to Thai News Agency, the FDA's authorization follows a comprehensive scientific evaluation, which included an assessment of the health risks posed by these nicotine pouches. The agency's announcement highlighted that these products, already available for sale in the U.S. through the Pre-Market Tobacco Application (PMTA) process, can now promote claims of reduced risk. Specifically, the marketing claims state that using nicotine pouches instead of cigarettes can lower the risk of oral cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.
Dr. Brett Kopaw, Acting Director of the FDA's Center for Tobacco Products, emphasized the importance of providing adult smokers with clear and evidence-based information about the harm reduction potential of nicotine pouches. He noted that marketing these products with reduced-risk messaging could help smokers make informed choices regarding their tobacco use.
The FDA's statement clarified that the MRTP authorization is specific to the approved products, which are available in 3 milligram and 6 milligram nicotine strengths. The agency's evaluation considered various factors, including consumer understanding of risk reduction messaging, potential risks to youth, and the overall impact on public health.
The FDA determined that the applicant provided sufficient scientific evidence to support the marketing claims and that such marketing would benefit public health. The authorization includes requirements for post-market surveillance and studies to monitor user behavior and understanding of the risks. This authorization is valid for five years, with the possibility of renewal. However, the FDA retains the right to revoke the authorization if it no longer benefits public health, particularly if there is a significant increase in youth use.
While the FDA acknowledges that no tobacco product is entirely safe, it advises adult smokers that quitting altogether is the best option for health. For those unable to quit, switching from smoking to FDA-approved nicotine pouches may reduce exposure to harmful chemicals found in cigarette smoke. To date, the FDA has approved 26 nicotine pouch products after rigorous evaluation, ensuring they meet legal public health standards.